Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levothyroxine sodium - Merck

X
Drug Profile

Levothyroxine sodium - Merck

Alternative Names: EUTHYROX; Eutirox NF® Merck; Eutirox®; Novothyrox

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck AG
  • Class Aromatic amino acids; Small molecules; Thyroid hormones
  • Mechanism of Action Hormone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypothyroidism

Most Recent Events

  • 13 Mar 2024 Launched for Hypothyroidism (In adolescents, In children, In the elderly, In infants, In neonates, In adults) in USA (PO) before March 2024 (Merck website, March 2024)
  • 13 Mar 2024 Launched for Hypothyroidism in Sweden, Spain, Slovakia, Slovenia, Romania, Portugal, Poland, Netherlands, Luxembourg, Latvia, Italy, Hungary, Greece, Germany, France, Denmark, Czech Republic, Cyprus, Croatia, Bulgaria, Austria, Belgium, Norway, Liechtenstein, Iceland, Turkey (PO) before March 2024 (Merck website, March 2024)
  • 13 Mar 2024 Launched for Hypothyroidism in Vietnam, Thailand, Singapore, Philippines, Malaysia, Indonesia, China, Brunei, Venezuela, Trinidad and Tobago, Peru, Panama, Nicaragua, Mexico, Jamaica, Honduras, Guatemala, El Salvador, Ecuador, Cuba, Dominican Republic, Costa Rica, Colombia, Chile, Brazil, Bolivia, Bahamas, Argentina, Yemen, Uzbekistan, Uzbekistan, Ukraine, United Arab Emirates, Uganda, Turkmenistan, Tunisia, Togo, Tanzania, Syria, Tajikistan, Sudan, South Africa, Serbia, Saudi Arabia, Senegal, Russia, Oman, Nigeria, Namibia, Mozambique, Montenegro, Moldova, Mauritania, Mali, Madagascar, Macedonia, Lebanon, Kuwait, Kyrgyzstan, Kenya, Kazakhstan, Jordan, Israel, Iran, Georgia, Gabon, Egypt, Ivory Coast, Congo, Burkina Faso, Bosnia-Herzegovina, Benin, Belarus, Bahrain, Azerbaijan, Armenia, Algeria, Angola, Algeria, Albania, Canada (PO) before March 2024 (Merck website, March 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top